RT Book, Section
A1 Kim, Nick H.
A1 Mandel, Jess
A1 Smith, Kimberly A.
A1 Yuan, Jason X.-J.
A2 Grippi, Michael A.
A2 Antin-Ozerkis, Danielle E.
A2 Dela Cruz, Charles S.
A2 Kotloff, Robert M.
A2 Kotton, Camille Nelson
A2 Pack, Allan I.
SR Print(0)
ID 1206603158
T1 Pulmonary Arterial Hypertension
T2 Fishman’s Pulmonary Diseases and Disorders, 6e
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781260473988
LK accessmedicine.mhmedical.com/content.aspx?aid=1206603158
RD 2024/04/23
AB Pulmonary  arterial  hypertension  (PAH)  is  a  progressive  disease  of  the  pulmonary  vasculature  that  results  in  right  heart  failure  and  excess  morbidity  and  mortality  without  effective  treatment.  Although  rapid  progress  has  resulted  in  the  availability  of  therapies  that  can  improve  the  outlook  for  many  patients,  true  full  reversal  of  disease  remains  elusive.  Furthermore,  long  delays  in  disease  recognition  are  common,  exposing  patients  to  prolonged  suffering  and  potentially  irreversible  harm.  PAH  should  not  be  confused  with  other  mechanisms  leading  to  elevation  of  pulmonary  arterial  pressure,  such  as  hypoxemic  lung  disorders  (e.g.,  chronic  obstructive  pulmonary  disease  [COPD],  interstitial  lung  disease  [ILD]),  left  heart  disease  (e.g.,  systolic,  diastolic,  or  valvular  dysfunctions),  or  chronic  thromboembolism.1,2  Prompt  and  accurate  diagnosis  of  PAH  followed  by  treatment  based  on  the  latest  evidence-based  guidelines  are  essential  in  successfully  managing  PAH.